CL2023001418A1 - Inhibidor de integrina y usos de este. - Google Patents
Inhibidor de integrina y usos de este.Info
- Publication number
- CL2023001418A1 CL2023001418A1 CL2023001418A CL2023001418A CL2023001418A1 CL 2023001418 A1 CL2023001418 A1 CL 2023001418A1 CL 2023001418 A CL2023001418 A CL 2023001418A CL 2023001418 A CL2023001418 A CL 2023001418A CL 2023001418 A1 CL2023001418 A1 CL 2023001418A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- inhibitors
- integrin inhibitor
- crystalline forms
- integrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116042P | 2020-11-19 | 2020-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001418A1 true CL2023001418A1 (es) | 2023-10-30 |
Family
ID=81709878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001418A CL2023001418A1 (es) | 2020-11-19 | 2023-05-17 | Inhibidor de integrina y usos de este. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12018025B2 (enExample) |
| EP (1) | EP4247472A4 (enExample) |
| JP (1) | JP2023550428A (enExample) |
| KR (1) | KR20230121761A (enExample) |
| CN (1) | CN116710169A (enExample) |
| AU (1) | AU2021381516A1 (enExample) |
| CA (1) | CA3173755A1 (enExample) |
| CL (1) | CL2023001418A1 (enExample) |
| CO (1) | CO2023006522A2 (enExample) |
| CR (1) | CR20230262A (enExample) |
| CU (1) | CU20230026A7 (enExample) |
| DO (1) | DOP2023000101A (enExample) |
| EC (1) | ECSP23045278A (enExample) |
| IL (1) | IL302651A (enExample) |
| JO (1) | JOP20230102A1 (enExample) |
| MX (1) | MX2023005889A (enExample) |
| PE (1) | PE20240114A1 (enExample) |
| TW (1) | TW202235417A (enExample) |
| WO (1) | WO2022109598A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| US20240122930A1 (en) * | 2022-07-09 | 2024-04-18 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| WO2024155965A2 (en) * | 2023-01-21 | 2024-07-25 | Pliant Therapeutics, Inc. | Biomarkers for use in integrin inhibitor therapy |
| US20250120975A1 (en) * | 2023-09-25 | 2025-04-17 | Pliant Therapeutics, Inc. | Integrin inhibitors for treatment of primary sclerosing cholangitis |
| US20250197393A1 (en) | 2023-12-14 | 2025-06-19 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
| WO2025217571A1 (en) * | 2024-04-12 | 2025-10-16 | Pliant Therapeutics, Inc. | Fixed dose combinations of integrin inhibitor with ppar agonists |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040105740A (ko) | 2002-02-25 | 2004-12-16 | 엘란 파마슈티칼스, 인크. | 염증 치료제의 투여 방법 |
| ES2416354T3 (es) | 2005-06-21 | 2013-07-31 | Ajinomoto Co., Inc. | Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo |
| WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| US8911952B2 (en) | 2010-03-24 | 2014-12-16 | Stc. Unm | Method for integrin ligand discovery |
| MA37711A1 (fr) * | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| IN2015DN00099A (enExample) | 2012-07-18 | 2015-05-29 | Univ Saint Louis | |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| JP2018514568A (ja) | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
| US10118929B2 (en) | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| WO2018183795A1 (en) | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
| CU24684B1 (es) * | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| JP7314135B2 (ja) * | 2018-07-20 | 2023-07-25 | 株式会社半導体エネルギー研究所 | 撮像装置 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| EP3843728B1 (en) | 2018-08-29 | 2025-04-30 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3903316A1 (en) * | 2018-12-28 | 2021-11-03 | LunaPBC | Community data aggregation, completion, correction, and use |
| EP3923857B8 (en) * | 2019-02-15 | 2024-04-17 | Clean Bite, LLC | Oral hygiene appliance |
| EP3952902A4 (en) * | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| CN115151566A (zh) | 2019-11-15 | 2022-10-04 | 普利安特治疗公司 | 用于活化整合素的组合物和方法 |
| KR20230049584A (ko) * | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
| TWI843503B (zh) * | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| TW202233224A (zh) * | 2020-10-21 | 2022-09-01 | 美商寇峇有限公司 | 用組合療法治療纖維化之方法 |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| US20230028658A1 (en) | 2021-04-30 | 2023-01-26 | Pliant Therapeutics, Inc. | Expanded dosage regimens for integrin inhibitors |
| US20240350494A1 (en) | 2021-09-03 | 2024-10-24 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
| JP2024539645A (ja) | 2021-10-14 | 2024-10-29 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン阻害剤及び他の薬剤と組み合わせたその使用 |
| WO2023225119A1 (en) | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
| US20240122930A1 (en) | 2022-07-09 | 2024-04-18 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| WO2024145245A2 (en) | 2022-12-27 | 2024-07-04 | Pliant Therapeutics, Inc. | Alpha-v-beta-8 integrin inhibitors and uses thereof |
| WO2024155965A2 (en) | 2023-01-21 | 2024-07-25 | Pliant Therapeutics, Inc. | Biomarkers for use in integrin inhibitor therapy |
-
2021
- 2021-11-19 TW TW110143265A patent/TW202235417A/zh unknown
- 2021-11-19 WO PCT/US2021/072510 patent/WO2022109598A1/en not_active Ceased
- 2021-11-19 JP JP2023530225A patent/JP2023550428A/ja active Pending
- 2021-11-19 PE PE2023001662A patent/PE20240114A1/es unknown
- 2021-11-19 KR KR1020237020570A patent/KR20230121761A/ko not_active Withdrawn
- 2021-11-19 EP EP21895890.8A patent/EP4247472A4/en not_active Withdrawn
- 2021-11-19 CU CU2023000026A patent/CU20230026A7/es unknown
- 2021-11-19 CN CN202180090550.5A patent/CN116710169A/zh active Pending
- 2021-11-19 CA CA3173755A patent/CA3173755A1/en active Pending
- 2021-11-19 MX MX2023005889A patent/MX2023005889A/es unknown
- 2021-11-19 US US17/531,074 patent/US12018025B2/en active Active
- 2021-11-19 CR CR20230262A patent/CR20230262A/es unknown
- 2021-11-19 IL IL302651A patent/IL302651A/en unknown
- 2021-11-19 AU AU2021381516A patent/AU2021381516A1/en not_active Abandoned
-
2023
- 2023-05-08 JO JOJO/P/2023/0102A patent/JOP20230102A1/ar unknown
- 2023-05-17 CL CL2023001418A patent/CL2023001418A1/es unknown
- 2023-05-17 CO CONC2023/0006522A patent/CO2023006522A2/es unknown
- 2023-05-18 DO DO2023000101A patent/DOP2023000101A/es unknown
- 2023-06-16 EC ECSENADI202345278A patent/ECSP23045278A/es unknown
-
2024
- 2024-03-27 US US18/619,017 patent/US12637462B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4247472A1 (en) | 2023-09-27 |
| MX2023005889A (es) | 2023-06-06 |
| US20220177468A1 (en) | 2022-06-09 |
| AU2021381516A9 (en) | 2024-10-24 |
| ECSP23045278A (es) | 2023-07-31 |
| DOP2023000101A (es) | 2023-09-29 |
| JOP20230102A1 (ar) | 2023-05-08 |
| CO2023006522A2 (es) | 2023-06-09 |
| CR20230262A (es) | 2023-07-26 |
| CN116710169A (zh) | 2023-09-05 |
| IL302651A (en) | 2023-07-01 |
| CA3173755A1 (en) | 2022-05-27 |
| US12018025B2 (en) | 2024-06-25 |
| JP2023550428A (ja) | 2023-12-01 |
| PE20240114A1 (es) | 2024-01-22 |
| TW202235417A (zh) | 2022-09-16 |
| EP4247472A4 (en) | 2024-10-09 |
| AU2021381516A1 (en) | 2023-06-22 |
| CU20230026A7 (es) | 2024-01-10 |
| KR20230121761A (ko) | 2023-08-21 |
| WO2022109598A1 (en) | 2022-05-27 |
| US12637462B2 (en) | 2026-05-26 |
| US20240391914A1 (en) | 2024-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23045278A (es) | Inhibidor de integrina y usos de este | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| ECSP109910A (es) | Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos | |
| EA202091774A1 (ru) | Гербицидно-активные 3-фенилизоксазолин-5-карбоксамиды производных циклопентенилкарбоновой кислоты | |
| UY39517A (es) | Inhibidores de la btk | |
| UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| PY1996328A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| UY35369A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| CR20120591A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| CO2018004933A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| PY2037133A (es) | Agonistas de receptores tipo toll | |
| CO2024013531A2 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CL2024001364A1 (es) | Inhibidores de pi3k-alfa y métodos para su producción y uso | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| CR20190344A (es) | Activador de nrf2 | |
| ECSP22083772A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| UY35536A (es) | ?derivados de sulfonamida?. | |
| MX2021012499A (es) | Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos. | |
| ECSP18056196A (es) | Derivados de indano | |
| DOP2022000179A (es) | Composiciones farmacéuticas de sales de éster de colina de ácido lipoico y métodos de tratamiento usando las mismas | |
| AR127447A1 (es) | Sales orgánicas para formulaciones agroquímicas |